Maroof Adil

Head of Disease Targeting at Scribe Therapeutics


Office Hours

How does this work?
Ask me about
Genome editing
Cell and gene therapies
Viral and non-viral gene delivery
Work experience

Apr 2021 - Present

Scribe Therapeutics

Director of Therapeutics Discovery

Leading a team of investigators to design and execute early stage discovery research in multiple therapeutic areas


Feb 2019 - Present

Scribe Therapeutics

Head of Disease Targeting

Working closely with scientific co-founders to set scientific vision, strategy, and culture of a rapidly growing biotechnology start up in therapeutic genome editing • Part of a 6-member core leadership team for scientific and business development • Leading a 7-member team of PhD level scientists and specialists in disease modeling • Quarterly presentation to Board of Directors on scientific progress and future direction • Contributing to grant writing, investor pitch decks, and patent writing


Nov 2018 - Feb 2019

Scribe Therapeutics


In a dynamic, fast-paced role as the first Scientist at a young, rapidly growing biotech start-up focused on developing the next-generation of therapies for human diseases. Responsibilities include working closely with co-founders to shape the scientific direction of the company, project management, market research, alliance management, and recruiting.


Sep 2013 - Nov 2018

UC Berkeley

Postdoctoral Research Scholar

Spearheaded stem cell-based technologies in the lab, trained and managed cross-functional research teams, secured internal and external funding, filed patents, and presented technical information to broad audiences. • Developed protocols to differentiate human pluripotent stem cells into cells of the central nervous system. • Developed regenerative therapies for Parkinson’s Disease, Huntington’s Disease, and Spinal Cord Injury; performed stereotaxic surgery and striatal cell transplantation, behavioral tests, perfusion, tissue harvest, and histology. • Generated in vitro models of neurodegenerative diseases with neural cells differentiated from patient derived iPSCs. • Designed functionalized hyaluronic-acid based biomaterial scaffolds for cell delivery to the brain. • Treated Huntington’s disease in animal models using CRISPR/Cas-based gene editing. • Generated iPSCs from fibroblasts to mechanistically understand reprogramming. • Led a 14-member multi-disciplinary team spanning industry and academia to understand stem cell biology using single-cell RNA sequencing.


Aug 2007 - Aug 2013

University of Minnesota

Chemical Engineering PhD Candidate

Combined engineering and biology as part of a cross-functional team to develop cancer therapies, and presented technical information to broad audiences. • Developed a nanoparticle-based vector for gene delivery to cancer cells. • Investigated transfection mechanisms to identify optimal design criteria for increased transfection efficiency.

Jan 2009 - Dec 2012

MIT Alumni Club of Minnesota

MIT'10 Chair

Socially connecting the MIT alumni in the Minnesota area with each other and with alumni from other schools in the local clubs


Jan 2004 - Dec 2006


Undergraduate Research Assistant

Development of polymeric microparticles to prevent post surgical peritoneal adhesion


Jun 2006 - Aug 2006


Summer Intern

Validated drug efficacy in cell-based assays

Talk to Maroof

@ Copyright 2020 OfficeHours Technologies Co.